Signature Diagnostics to Present Company's Blood-Based Colorectal Cancer Screening Strategy at the 18th UEGW Congress in Barcelona
(Thomson Reuters ONE) -
Signature Diagnostics /
Signature Diagnostics to Present Company's Blood-Based Colorectal Cancer
Screening Strategy at the 18th UEGW Congress in Barcelona
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
* Advantages of Detector C and Detector C/Plus in early detection of CRC
Potsdam, Germany, October 26, 2010 - Signature Diagnostics AG announced today
that the company was selected to present its newest blood-based products for
colorectal cancer (CRC) screening -- Detector C and Detector C/Plus -- at the
18th United European Gastrointestinal Week (UEGW) Congress in Barcelona on
October 22-26, 2010. The paper, "Early Detection of Colorectal Cancer Based on
RNA Measurements in Blood," will be presented by the company's CEO, André
Rosenthal, Ph.D, at the session "Colorectal Cancer Screening: New Strategies" on
Wednesday, October 26, 2010 (Hall 14, 8:30-10:30am).
Both Detector C and Detector C/Plus are extremely accurate and safe with a
validated sensitivity of 90 percent and a validated specificity of up to 92.5
percent. Both tests should be applicable to individuals who dislike colonoscopy
due to bowel cleaning and its invasiveness, dislike stool-based tests, or are
above 70-years-old and may have conditions that increase the risks of
colonoscopy and side effects.
"The use of Detector C and Detector C/Plus as primary screening tools not only
increases sensitivity and specificity of blood-based CRC screening, but would
result in significantly fewer unnecessary colonoscopies in countries where
screening colonoscopy is reimbursed," said André Rosenthal. "The test's low
false positive rate of 7.5 percent is close to that of colonoscopy and ensures
that endoscopy resources will not be exhausted by large-scale use of this blood-
based test."
About Signature Diagnostics AG
Signature Diagnostics AG is a molecular diagnostics company based in Potsdam,
Germany, focusing on the development and commercialization of novel molecular
oncology diagnostic products for early detection (screening) and prognosis of
cancer. The company has completed development of its first two diagnostic
products for colorectal cancer screening ("Detector C/C+") and prognosis
("Predictor C"), which will be launched in early 2011 in its own ISO 15189
certified service laboratory. Using its state-of-the-art technologies in tissue
and blood sample collection, molecular pathology, Xenopatient(TM) platform,
genome-wide profiling, data mining, and biostatistics, the company collaborates
with clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics
sponsors and conducts large prospective, multicenter clinical trials with more
than 25 primary care hospitals and several dozen colonoscopy centers in Germany
to discover and validate biomarkers in oncology.
For questions, please contact:
Prof. Dr. André Rosenthal, CEO
Signature Diagnostics
Hermannswerder 20A
14473 Potsdam, Germany
Tel: +49-331-2000-208
PR(at)signature-diagnostics.de
[HUG#1455579]
--- End of Message ---
Signature Diagnostics
Hermannswerder 20 A Potsdam Germany
Press release (PDF):
http://hugin.info/143237/R/1455579/395446.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 26.10.2010 - 19:43 Uhr
Sprache: Deutsch
News-ID 46318
Anzahl Zeichen: 0
contact information:
Town:
Potsdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Signature Diagnostics to Present Company's Blood-Based Colorectal Cancer Screening Strategy at the 18th UEGW Congress in Barcelona"
steht unter der journalistisch-redaktionellen Verantwortung von
Signature Diagnostics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
